Novartis India announces a leadership change

The specific Open Offer price announced in the public disclosures is Rs 860.64 per share ^[1].

Valuation Comparison

• Promoter Acquisition Price: The Open Offer price of Rs 860.64 per share matches the highest negotiated price under the Share Purchase Agreement (SPA) for acquiring the promoter's (Novartis AG) 70.68% stake (1,74,50,680 equity shares) ^[2]. The total consideration for the promoter stake sale was pegged at approximately Rs 1,445.89 Crores ^[1]. Within the multi-party structure of the acquiring consortium, specific tranches involved differing terms, such as an onshore price of Rs 701.25 per share for Acquirer 3 ^[3], while the open offer benchmark and primary block acquisition relied on the Rs 860.64 ceiling ^[4].
• Trailing Book Value: Compared to the company's trailing standalone book value per share of Rs 66.27 (reported at the end of Q4 FY26) ^[5], the Open Offer price represents a substantial premium. This implies an acquisition price-to-book multiple of approximately 12.98x (derived from the offer price of Rs 860.64 and book value of Rs 66.27 ^[5]).

Implication

The steep valuation multiple over trailing book value reflects the control premium paid by the incoming private equity consortium (WaveRise, ChrysCapital Fund X, and Two Infinity Partners) ^[2]. It highlights that the acquirers are pricing the buyout based on strategic optionality, brand transition potential, and liquid asset backing rather than historical book carrying values or trailing earnings alone.

As part of the acquisition of Novartis India Limited (NIL) by the ChrysCapital-led consortium from Novartis AG, specific commercial and transition arrangements were structured to address portfolio continuity, supply tenure, and intellectual property terms ^[6], ^[4].

Continuity, Tenure, and Royalty Terms

• Trademark Licensing: Novartis AG entered into a royalty-free, irrevocable license for the *Tegrital* trademark, securing ongoing brand usage rights for the portfolio post-acquisition ^[6].
• Distribution and Supply Tenure: The parties established a five-year distribution agreement to maintain the supply of certain products into the Indian market, ensuring uninterrupted patient access and supply chain stability during the handover ^[6].
• Covenant and Commercial Agreements: In conjunction with the Share Purchase Agreement (SPA) dated February 19, 2026, the acquirers entered into a company covenant and warranty deed, alongside commercial agreements executed at closing to facilitate the orderly transition of the business and govern the assignment or licensing of intellectual property rights in favor of the target company ^[4].

Implication

The five-year distribution tenure and royalty-free trademark terms provide near-term operational visibility and mitigate supply shocks for core legacy brands (*Tegrital*, *Voveran*, *Calcium Sandoz*) as the company shifts from a multinational parent model to a domestic branded-generics platform ^[6]. At the same time, the finite five-year window on the distribution agreement creates a structural imperative for the new promoter (ChrysCapital) to establish independent sourcing, local manufacturing, or alternate supply arrangements before the transition agreements expire.

The Share Purchase Agreement (SPA) dated February 19, 2026, executed between Novartis AG and the acquirer consortium (WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners), outlined specific Conditions Precedent (CPs) that were required to be satisfied prior to transaction closing ^[7].

Conditions Precedent under the SPA

• Regulatory and Legal Clearances: No law, judgment, injunction, decree, or order from any competent governmental entity could be in effect that prohibited or rendered illegal the execution of the SPA, transaction documents, or the consummation of the transaction ^[8].
• Covenant Compliance: The seller (Novartis AG) and the target company must not have breached in any material respect their respective covenants under the SPA and the Covenant Warranty Deed ^[8].
• Accuracy of Warranties: All warranties provided by the seller and fundamental warranties provided by the target company in the SPA and the Covenant Warranty Deed had to remain true, accurate, and not misleading both as of the execution date and the closing date ^[8].
• Tax Proceedings and Withholding Reports: An agreed-form report detailing pending tax proceedings against the seller under the Indian Income Tax Act, 1961, along with a computed tax withholding report, had to be finalized ^[8].
• Commercial Agreement Warranties: Statements in warranties provided by the seller under specified commercial agreements must remain true, accurate, and not misleading as of the closing date ^[8].

Stipulated Timeline for the Mandatory Open Offer

The mandatory open offer process under SEBI (SAST) Regulations followed a structured schedule leading up to its final conclusion:

• Detailed Public Statement (DPS): Published on February 26, 2026 ^[9].
• Identified Date: May 27, 2026 (defined as the 10th working day prior to the commencement of the tendering period) ^[9].
• Tendering Period: 10 working days running from Thursday, June 11, 2026, to Wednesday, June 24, 2026 (both days inclusive) ^[9].
• Conclusion Date: The open offer officially concluded on July 29, 2026, coinciding with the closing date of the underlying share purchase transaction and formal board approval of the change in control ^[10].